Loading…

Evidence for a role of D1 dopamine receptors in d-amphetamine's effect on timing behaviour in the free-operant psychophysical procedure

Temporal differentiation of operant behaviour is sensitive to dopaminergic manipulations. Studies using the fixed-interval peak procedure implicated D2 dopamine receptors in these effects. Less is known about the effects of dopaminergic manipulations on temporal differentiation in other timing sched...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacologia 2006-04, Vol.185 (3), p.378-388
Main Authors: CHEUNG, T. H. C, BEZZINA, G, ASGARI, K, BODY, S, FONE, K. C. F, BRADSHAW, C. M, SZABADI, E
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c271t-1ff08dc92ac3bf537d7b3271e170b9aa9fe9db430ba2611f44f13ef5d0ea3e0f3
cites cdi_FETCH-LOGICAL-c271t-1ff08dc92ac3bf537d7b3271e170b9aa9fe9db430ba2611f44f13ef5d0ea3e0f3
container_end_page 388
container_issue 3
container_start_page 378
container_title Psychopharmacologia
container_volume 185
creator CHEUNG, T. H. C
BEZZINA, G
ASGARI, K
BODY, S
FONE, K. C. F
BRADSHAW, C. M
SZABADI, E
description Temporal differentiation of operant behaviour is sensitive to dopaminergic manipulations. Studies using the fixed-interval peak procedure implicated D2 dopamine receptors in these effects. Less is known about the effects of dopaminergic manipulations on temporal differentiation in other timing schedules. To examine the effects of a D1 antagonist,8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol (SKF-83566), and a D2 antagonist, haloperidol, on performance on the free-operant psychophysical procedure, and the ability of these antagonists to reverse the effects of the catecholamine-releasing agent, d-amphetamine on performance. The antagonists' ability to reverse d-amphetamine-induced hyperlocomotion was also examined. Rats responded on two levers (A and B) under a free-operant psychophysical schedule, in which reinforcement was provided intermittently for responding on A during the first half, and B during the second half, of 50-s trials. Logistic functions were fitted to the relative response rate data (percent responding on B [%B] vs time [t]) in each treatment condition, and quantitative timing indices [T50 (value of t corresponding to %B=50) and Weber fraction] were compared among treatments. Effects of the treatments on locomotion were measured in a separate experiment. SKF-83566 (0.015, 0.03, 0.06 mg kg(-1)) did not affect timing performance. Haloperidol (0.025, 0.05 mg kg(-1)) had no effect; a higher dose (0.1 mg kg(-1)) reduced T (50). d-Amphetamine (0.4 mg kg(-1)) reduced T50; this effect was antagonised by SKF-83566 but not by haloperidol. Both antagonists reduced d-amphetamine-induced hyperlocomotion. The results suggest that d-amphetamine's effect on performance in the free-operant psychophysical procedure is mediated by D1 rather than D2 receptors.
doi_str_mv 10.1007/s00213-006-0339-x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67776707</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1035151981</sourcerecordid><originalsourceid>FETCH-LOGICAL-c271t-1ff08dc92ac3bf537d7b3271e170b9aa9fe9db430ba2611f44f13ef5d0ea3e0f3</originalsourceid><addsrcrecordid>eNpdkU2LFDEQhoMo7rj6A7xIENRTtPIxne6jrOsHLHjRc0gnFTtLd6dNupedX-DfNuMMLFiXgqqn3krqJeQlh_ccQH8oAIJLBtAwkLJj94_IjispmAAtHpMd1CqTfN9ekGel3EIN1aqn5II3e9kqDTvy5_ouepwd0pAytTSnEWkK9BOnPi12ijPSjA6XNeVC40w9s9My4Pqv9a5QDAHdStNM11hLv2iPg72LactHeh2qcEZkacFs55Uu5eCGtAyHEp0d6ZKTQ79lfE6eBDsWfHHOl-Tn5-sfV1_Zzfcv364-3jAnNF8ZDwFa7zphnezDXmqve1k7yDX0nbVdwM73SkJvRcN5UCpwiWHvAa1ECPKSvD3p1s2_NyyrmWJxOI52xrQV02itGw26gq__A2_rn-b6NiN422klhKoQP0Eup1IyBrPkONl8MBzM0SJzsshUi8zRInNfZ16dhbd-Qv8wcfakAm_OgC31RqHezcXywOlGiQrKv8shm2Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218974224</pqid></control><display><type>article</type><title>Evidence for a role of D1 dopamine receptors in d-amphetamine's effect on timing behaviour in the free-operant psychophysical procedure</title><source>Springer Link</source><source>SPORTDiscus with Full Text</source><creator>CHEUNG, T. H. C ; BEZZINA, G ; ASGARI, K ; BODY, S ; FONE, K. C. F ; BRADSHAW, C. M ; SZABADI, E</creator><creatorcontrib>CHEUNG, T. H. C ; BEZZINA, G ; ASGARI, K ; BODY, S ; FONE, K. C. F ; BRADSHAW, C. M ; SZABADI, E</creatorcontrib><description>Temporal differentiation of operant behaviour is sensitive to dopaminergic manipulations. Studies using the fixed-interval peak procedure implicated D2 dopamine receptors in these effects. Less is known about the effects of dopaminergic manipulations on temporal differentiation in other timing schedules. To examine the effects of a D1 antagonist,8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol (SKF-83566), and a D2 antagonist, haloperidol, on performance on the free-operant psychophysical procedure, and the ability of these antagonists to reverse the effects of the catecholamine-releasing agent, d-amphetamine on performance. The antagonists' ability to reverse d-amphetamine-induced hyperlocomotion was also examined. Rats responded on two levers (A and B) under a free-operant psychophysical schedule, in which reinforcement was provided intermittently for responding on A during the first half, and B during the second half, of 50-s trials. Logistic functions were fitted to the relative response rate data (percent responding on B [%B] vs time [t]) in each treatment condition, and quantitative timing indices [T50 (value of t corresponding to %B=50) and Weber fraction] were compared among treatments. Effects of the treatments on locomotion were measured in a separate experiment. SKF-83566 (0.015, 0.03, 0.06 mg kg(-1)) did not affect timing performance. Haloperidol (0.025, 0.05 mg kg(-1)) had no effect; a higher dose (0.1 mg kg(-1)) reduced T (50). d-Amphetamine (0.4 mg kg(-1)) reduced T50; this effect was antagonised by SKF-83566 but not by haloperidol. Both antagonists reduced d-amphetamine-induced hyperlocomotion. The results suggest that d-amphetamine's effect on performance in the free-operant psychophysical procedure is mediated by D1 rather than D2 receptors.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-006-0339-x</identifier><identifier>PMID: 16538470</identifier><identifier>CODEN: PSYPAG</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - analogs &amp; derivatives ; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology ; Amphetamines ; Animals ; Biological and medical sciences ; Conditioning, Operant - drug effects ; Dextroamphetamine - pharmacology ; Dopamine ; Dopamine D2 Receptor Antagonists ; Dose-Response Relationship, Drug ; Female ; Haloperidol - pharmacology ; Medical sciences ; Motor Activity - drug effects ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Rats ; Rats, Wistar ; Receptors, Dopamine D1 - antagonists &amp; inhibitors ; Receptors, Dopamine D1 - physiology ; Receptors, Dopamine D2 - physiology ; Response rates ; Schedules ; Time Perception - drug effects</subject><ispartof>Psychopharmacologia, 2006-04, Vol.185 (3), p.378-388</ispartof><rights>2006 INIST-CNRS</rights><rights>Springer-Verlag 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c271t-1ff08dc92ac3bf537d7b3271e170b9aa9fe9db430ba2611f44f13ef5d0ea3e0f3</citedby><cites>FETCH-LOGICAL-c271t-1ff08dc92ac3bf537d7b3271e170b9aa9fe9db430ba2611f44f13ef5d0ea3e0f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17642847$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16538470$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHEUNG, T. H. C</creatorcontrib><creatorcontrib>BEZZINA, G</creatorcontrib><creatorcontrib>ASGARI, K</creatorcontrib><creatorcontrib>BODY, S</creatorcontrib><creatorcontrib>FONE, K. C. F</creatorcontrib><creatorcontrib>BRADSHAW, C. M</creatorcontrib><creatorcontrib>SZABADI, E</creatorcontrib><title>Evidence for a role of D1 dopamine receptors in d-amphetamine's effect on timing behaviour in the free-operant psychophysical procedure</title><title>Psychopharmacologia</title><addtitle>Psychopharmacology (Berl)</addtitle><description>Temporal differentiation of operant behaviour is sensitive to dopaminergic manipulations. Studies using the fixed-interval peak procedure implicated D2 dopamine receptors in these effects. Less is known about the effects of dopaminergic manipulations on temporal differentiation in other timing schedules. To examine the effects of a D1 antagonist,8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol (SKF-83566), and a D2 antagonist, haloperidol, on performance on the free-operant psychophysical procedure, and the ability of these antagonists to reverse the effects of the catecholamine-releasing agent, d-amphetamine on performance. The antagonists' ability to reverse d-amphetamine-induced hyperlocomotion was also examined. Rats responded on two levers (A and B) under a free-operant psychophysical schedule, in which reinforcement was provided intermittently for responding on A during the first half, and B during the second half, of 50-s trials. Logistic functions were fitted to the relative response rate data (percent responding on B [%B] vs time [t]) in each treatment condition, and quantitative timing indices [T50 (value of t corresponding to %B=50) and Weber fraction] were compared among treatments. Effects of the treatments on locomotion were measured in a separate experiment. SKF-83566 (0.015, 0.03, 0.06 mg kg(-1)) did not affect timing performance. Haloperidol (0.025, 0.05 mg kg(-1)) had no effect; a higher dose (0.1 mg kg(-1)) reduced T (50). d-Amphetamine (0.4 mg kg(-1)) reduced T50; this effect was antagonised by SKF-83566 but not by haloperidol. Both antagonists reduced d-amphetamine-induced hyperlocomotion. The results suggest that d-amphetamine's effect on performance in the free-operant psychophysical procedure is mediated by D1 rather than D2 receptors.</description><subject>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - analogs &amp; derivatives</subject><subject>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology</subject><subject>Amphetamines</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Conditioning, Operant - drug effects</subject><subject>Dextroamphetamine - pharmacology</subject><subject>Dopamine</subject><subject>Dopamine D2 Receptor Antagonists</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Haloperidol - pharmacology</subject><subject>Medical sciences</subject><subject>Motor Activity - drug effects</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptors, Dopamine D1 - antagonists &amp; inhibitors</subject><subject>Receptors, Dopamine D1 - physiology</subject><subject>Receptors, Dopamine D2 - physiology</subject><subject>Response rates</subject><subject>Schedules</subject><subject>Time Perception - drug effects</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNpdkU2LFDEQhoMo7rj6A7xIENRTtPIxne6jrOsHLHjRc0gnFTtLd6dNupedX-DfNuMMLFiXgqqn3krqJeQlh_ccQH8oAIJLBtAwkLJj94_IjispmAAtHpMd1CqTfN9ekGel3EIN1aqn5II3e9kqDTvy5_ouepwd0pAytTSnEWkK9BOnPi12ijPSjA6XNeVC40w9s9My4Pqv9a5QDAHdStNM11hLv2iPg72LactHeh2qcEZkacFs55Uu5eCGtAyHEp0d6ZKTQ79lfE6eBDsWfHHOl-Tn5-sfV1_Zzfcv364-3jAnNF8ZDwFa7zphnezDXmqve1k7yDX0nbVdwM73SkJvRcN5UCpwiWHvAa1ECPKSvD3p1s2_NyyrmWJxOI52xrQV02itGw26gq__A2_rn-b6NiN422klhKoQP0Eup1IyBrPkONl8MBzM0SJzsshUi8zRInNfZ16dhbd-Qv8wcfakAm_OgC31RqHezcXywOlGiQrKv8shm2Y</recordid><startdate>200604</startdate><enddate>200604</enddate><creator>CHEUNG, T. H. C</creator><creator>BEZZINA, G</creator><creator>ASGARI, K</creator><creator>BODY, S</creator><creator>FONE, K. C. F</creator><creator>BRADSHAW, C. M</creator><creator>SZABADI, E</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>200604</creationdate><title>Evidence for a role of D1 dopamine receptors in d-amphetamine's effect on timing behaviour in the free-operant psychophysical procedure</title><author>CHEUNG, T. H. C ; BEZZINA, G ; ASGARI, K ; BODY, S ; FONE, K. C. F ; BRADSHAW, C. M ; SZABADI, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c271t-1ff08dc92ac3bf537d7b3271e170b9aa9fe9db430ba2611f44f13ef5d0ea3e0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - analogs &amp; derivatives</topic><topic>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology</topic><topic>Amphetamines</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Conditioning, Operant - drug effects</topic><topic>Dextroamphetamine - pharmacology</topic><topic>Dopamine</topic><topic>Dopamine D2 Receptor Antagonists</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Haloperidol - pharmacology</topic><topic>Medical sciences</topic><topic>Motor Activity - drug effects</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptors, Dopamine D1 - antagonists &amp; inhibitors</topic><topic>Receptors, Dopamine D1 - physiology</topic><topic>Receptors, Dopamine D2 - physiology</topic><topic>Response rates</topic><topic>Schedules</topic><topic>Time Perception - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHEUNG, T. H. C</creatorcontrib><creatorcontrib>BEZZINA, G</creatorcontrib><creatorcontrib>ASGARI, K</creatorcontrib><creatorcontrib>BODY, S</creatorcontrib><creatorcontrib>FONE, K. C. F</creatorcontrib><creatorcontrib>BRADSHAW, C. M</creatorcontrib><creatorcontrib>SZABADI, E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database (ProQuest)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Psychopharmacologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHEUNG, T. H. C</au><au>BEZZINA, G</au><au>ASGARI, K</au><au>BODY, S</au><au>FONE, K. C. F</au><au>BRADSHAW, C. M</au><au>SZABADI, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evidence for a role of D1 dopamine receptors in d-amphetamine's effect on timing behaviour in the free-operant psychophysical procedure</atitle><jtitle>Psychopharmacologia</jtitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2006-04</date><risdate>2006</risdate><volume>185</volume><issue>3</issue><spage>378</spage><epage>388</epage><pages>378-388</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><coden>PSYPAG</coden><abstract>Temporal differentiation of operant behaviour is sensitive to dopaminergic manipulations. Studies using the fixed-interval peak procedure implicated D2 dopamine receptors in these effects. Less is known about the effects of dopaminergic manipulations on temporal differentiation in other timing schedules. To examine the effects of a D1 antagonist,8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol (SKF-83566), and a D2 antagonist, haloperidol, on performance on the free-operant psychophysical procedure, and the ability of these antagonists to reverse the effects of the catecholamine-releasing agent, d-amphetamine on performance. The antagonists' ability to reverse d-amphetamine-induced hyperlocomotion was also examined. Rats responded on two levers (A and B) under a free-operant psychophysical schedule, in which reinforcement was provided intermittently for responding on A during the first half, and B during the second half, of 50-s trials. Logistic functions were fitted to the relative response rate data (percent responding on B [%B] vs time [t]) in each treatment condition, and quantitative timing indices [T50 (value of t corresponding to %B=50) and Weber fraction] were compared among treatments. Effects of the treatments on locomotion were measured in a separate experiment. SKF-83566 (0.015, 0.03, 0.06 mg kg(-1)) did not affect timing performance. Haloperidol (0.025, 0.05 mg kg(-1)) had no effect; a higher dose (0.1 mg kg(-1)) reduced T (50). d-Amphetamine (0.4 mg kg(-1)) reduced T50; this effect was antagonised by SKF-83566 but not by haloperidol. Both antagonists reduced d-amphetamine-induced hyperlocomotion. The results suggest that d-amphetamine's effect on performance in the free-operant psychophysical procedure is mediated by D1 rather than D2 receptors.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>16538470</pmid><doi>10.1007/s00213-006-0339-x</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0033-3158
ispartof Psychopharmacologia, 2006-04, Vol.185 (3), p.378-388
issn 0033-3158
1432-2072
language eng
recordid cdi_proquest_miscellaneous_67776707
source Springer Link; SPORTDiscus with Full Text
subjects 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - analogs & derivatives
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology
Amphetamines
Animals
Biological and medical sciences
Conditioning, Operant - drug effects
Dextroamphetamine - pharmacology
Dopamine
Dopamine D2 Receptor Antagonists
Dose-Response Relationship, Drug
Female
Haloperidol - pharmacology
Medical sciences
Motor Activity - drug effects
Neuropharmacology
Pharmacology. Drug treatments
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Rats
Rats, Wistar
Receptors, Dopamine D1 - antagonists & inhibitors
Receptors, Dopamine D1 - physiology
Receptors, Dopamine D2 - physiology
Response rates
Schedules
Time Perception - drug effects
title Evidence for a role of D1 dopamine receptors in d-amphetamine's effect on timing behaviour in the free-operant psychophysical procedure
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T15%3A29%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evidence%20for%20a%20role%20of%20D1%20dopamine%20receptors%20in%20d-amphetamine's%20effect%20on%20timing%20behaviour%20in%20the%20free-operant%20psychophysical%20procedure&rft.jtitle=Psychopharmacologia&rft.au=CHEUNG,%20T.%20H.%20C&rft.date=2006-04&rft.volume=185&rft.issue=3&rft.spage=378&rft.epage=388&rft.pages=378-388&rft.issn=0033-3158&rft.eissn=1432-2072&rft.coden=PSYPAG&rft_id=info:doi/10.1007/s00213-006-0339-x&rft_dat=%3Cproquest_cross%3E1035151981%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c271t-1ff08dc92ac3bf537d7b3271e170b9aa9fe9db430ba2611f44f13ef5d0ea3e0f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=218974224&rft_id=info:pmid/16538470&rfr_iscdi=true